Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. The company has invested significantly in subsidiaries and capex, including INR150 crores for a new performance chemicals plant and INR30 crores for pharma intermediates. Investments in the subsidiary (CFCL) have been funded by the parent company, with a total infusion of INR435 crores as of now. No indication from management about raising external funds through equity or debt during this period. Focus appears to be on internal funding and organic growth through capex and product commer

Any current/future capex/capital investment/strategic investment?

Q1 FY'25 capex of ~INR100 crores primarily invested in subsidiary Clean Fino-Chem Limited (CFCL). Pharma intermediates plant: INR30 crores capex, expected commercialization by Q3 FY'25. Performance Chemicals segment: - INR150 crores capex plant under construction at subsidiary, targeting commercialization by H1 FY'26, expected to address 15% of global market demand. - Another INR150 crores capex starting September 2024, focusing on water treatment chemicals, with 10-12 months construction and water trials timeline. Total planned capex around INR300 crores across these projects, with some

Future growth expectations in sales/revenue/volumes?

HALS segment volume target: Aspirational ramp-up to 150-200 tons per month in coming months; aiming for ~2,000 tons sales volume in FY'25 and 2,500-3,000 tons by FY'26 (50% capacity utilization). Revenue from new HALS capacity aimed at $7-$8/kg realization. Performance Chemicals segment and other products like MEHQ, DCC, TBHQ showing growing volumes and utilization around 65-70%. Volume growth is the primary driver for revenue increase; price realizations remain stable or slightly lower. Plans for INR 300 crore capex in FY'25 to expand capacities mainly in Performance Chemicals and Pharma inte

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth is expected to be primarily volume-led, with price realizations remaining steady or slightly lower. EBITDA margins have shown improvement sequentially due to better product mix and expense control; further margin expansion is anticipated as new plant capacities scale up. New capex plans include INR300 crores across pharma and performance chemicals segments, with commercialization expected by Q3 FY'25 and H1 FY'26, targeting about 15% of market demand. HALS segment volume is projected to increase from current ~125 tons/month towards 150-200 tons/month in the near term, with an ai

Current/ Expected Orderbook/ Pending Orders?

The company currently has around INR 300 crores to INR 400 crores of projects commissioned and in the pipeline (Page 14). There is an ongoing INR 300 crores capex planned primarily in the performance chemicals segment, to be executed within FY'25 and partly spilling over to FY'26 first half (Pages 12-13). Capex includes investments to expand capacity and commercialization of new products in pharma intermediates, water treatment chemicals, and performance chemicals (Pages 10-13). The INR 150 crores capex for novel process and water treatment segment is underway (Page 11). The subsidiary, CFCL,

IN US

Sale is live|00:00:00left today

Clean Science & Technology LtdQ2 FY24Chemicals & Petrochemicals

Clean Science & Technology Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹770P/E: 35.5Market Cap: ₹8.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→HALS segment volume target: Aspirational ramp-up to 150-200 tons per month in coming months; aiming for ~2,000 tons sales volume in FY'25 and 2,500-3,000 tons by FY'26 (50% capacity utilization).
→Revenue from new HALS capacity aimed at $7-$8/kg realization.
→Performance Chemicals segment and other products like MEHQ, DCC, TBHQ showing growing volumes and utilization around 65-70%.
→Volume growth is the primary driver for revenue increase; price realizations remain stable or slightly lower.
→Plans for INR 300 crore capex in FY'25 to expand capacities mainly in Performance Chemicals and Pharma intermediates, expected to enhance future sales.
→Targeting 70-75% of the Indian HALS market with expansion into Asian, American, and European export markets.
→Sustained quarter-on-quarter volume growth expected, with ongoing ramp-up of commercial production and new product launches supporting revenue growth.

Margin guidance

Category 3

→Revenue growth is expected to be primarily volume-led, with price realizations remaining steady or slightly lower.
→EBITDA margins have shown improvement sequentially due to better product mix and expense control; further margin expansion is anticipated as new plant capacities scale up.
→New capex plans include INR300 crores across pharma and performance chemicals segments, with commercialization expected by Q3 FY'25 and H1 FY'26, targeting about 15% of market demand.
→HALS segment volume is projected to increase from current ~125 tons/month towards 150-200 tons/month in the near term, with an aim to reach 50-80% capacity utilization within 3-4 years.
→Consolidated profitability currently impacted by start-up costs in subsidiary but expected to improve as new products gain traction.
→Overall, performance chemicals, pharma intermediates, and FMCG chemical segments show positive volume growth prospects underpinning future earnings expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
→The company has invested significantly in subsidiaries and capex, including INR150 crores for a new performance chemicals plant and INR30 crores for pharma intermediates.
→Investments in the subsidiary (CFCL) have been funded by the parent company, with a total infusion of INR435 crores as of now.
→No indication from management about raising external funds through equity or debt during this period.
→Focus appears to be on internal funding and organic growth through capex and product commercialization.

Order book

→The company currently has around INR 300 crores to INR 400 crores of projects commissioned and in the pipeline (Page 14).
→There is an ongoing INR 300 crores capex planned primarily in the performance chemicals segment, to be executed within FY'25 and partly spilling over to FY'26 first half (Pages 12-13).
→Capex includes investments to expand capacity and commercialization of new products in pharma intermediates, water treatment chemicals, and performance chemicals (Pages 10-13).
→The INR 150 crores capex for novel process and water treatment segment is underway (Page 11).
→The subsidiary, CFCL, has received total infusion of INR 435 crores to date and houses HALS plants with about INR 350 crores in fixed assets (Page 12).
→Decisions on additional capacity expansion, especially of legacy products, will be evaluated by end of 2024 (Page 13-14).

Capex plans

Yes

→Q1 FY'25 capex of ~INR100 crores primarily invested in subsidiary Clean Fino-Chem Limited (CFCL).
→Pharma intermediates plant: INR30 crores capex, expected commercialization by Q3 FY'25.
→Performance Chemicals segment:
→ - INR150 crores capex plant under construction at subsidiary, targeting commercialization by H1 FY'26, expected to address 15% of global market demand.
→ - Another INR150 crores capex starting September 2024, focusing on water treatment chemicals, with 10-12 months construction and water trials timeline.
→Total planned capex around INR300 crores across these projects, with some spillover into FY'26.
→Future capex decisions for legacy products and capacity expansion to be evaluated by end of 2024 based on market absorption.
→Additional investment planned in 6 MW solar plant to improve ESG and reduce power costs.

How does Clean Science & Technology Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Clean Science & Technology Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Clean Science & Technology Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio